P37.0 Congenital tuberculosis

Name of the Condition

• Congenital tuberculosis (ICD-10-CM Code: P37.0)

Summary

Congenital tuberculosis is a rare infection in newborns caused by the bacterium Mycobacterium tuberculosis, acquired from the mother during pregnancy or delivery. The condition can affect multiple organ systems and requires prompt diagnosis and treatment to prevent severe outcomes.

Causes

The infection is transmitted from the mother to the fetus via the placenta, amniotic fluid, or during delivery. Maternal tuberculosis, particularly active pulmonary or extrapulmonary disease, is the primary source of transmission. The bacterium can cross the placental barrier or be inhaled during birth if the mother has active respiratory tuberculosis.

Risk Factors

• Maternal active tuberculosis, especially with untreated or poorly controlled disease
• Lack of prenatal screening for tuberculosis in high-risk populations
• Close contact with individuals with active tuberculosis during pregnancy
• Immunocompromised maternal status (e.g., HIV, diabetes)

Symptoms

Symptoms may appear within the first few weeks of life and can include:

• Fever, poor feeding, or failure to thrive
• Respiratory distress, cough, or tachypnea
• Hepatosplenomegaly (enlarged liver and spleen)
• Lymphadenopathy (swollen lymph nodes)
• Skin lesions or rash
• Neurological signs (e.g., irritability, seizures)

Diagnosis

Diagnosis involves a combination of clinical evaluation, maternal history, and laboratory testing. Key steps include: Review of maternal tuberculosis status and treatment history. Newborn physical examination for signs of infection. Chest X-ray or imaging to assess for pulmonary or extrapulmonary involvement. Laboratory tests: acid-fast bacilli (AFB) smear, culture, or nucleic acid amplification (e.g., PCR) from bodily fluids (e.g., gastric aspirate, cerebrospinal fluid) Tuberculin skin test (TST) or interferon-gamma release assay (IGRA) may be used, though results can be delayed in infants.

Treatment Options

Treatment typically involves a multidrug regimen tailored to the infant's age and disease severity. Standard therapy includes isoniazid, rifampin, pyrazinamide, and ethambutol, often administered for 6–12 months. Close monitoring for drug toxicity and adherence to the regimen is critical. In cases of maternal drug resistance, alternative regimens may be necessary.

Prognosis and Follow-Up

With early diagnosis and appropriate treatment, outcomes can be favorable, but delays in care increase the risk of severe complications or mortality. Follow-up includes regular clinical assessments, monitoring for treatment response, and evaluation for potential long-term effects (e.g., neurodevelopmental delays). Infants may require ongoing surveillance for recurrence or latent infection.

Complications

• Disseminated disease (affecting multiple organs)
• Meningitis or central nervous system involvement
• Respiratory failure
• Growth failure or developmental delays
• Drug-resistant tuberculosis (if maternal strain is resistant)

Lifestyle & Prevention

• Maternal screening and treatment for tuberculosis during pregnancy to reduce transmission risk
• Postnatal isolation of the infant from the mother if she has active, contagious tuberculosis until she is no longer infectious
• Vaccination of infants with BCG (Bacille Calmette-Guérin) in regions with high tuberculosis prevalence, though its efficacy in preventing congenital infection is limited
• Avoidance of exposure to individuals with active tuberculosis during pregnancy and the neonatal period

When to Seek Professional Help

Seek immediate medical attention if a newborn shows signs of infection (e.g., fever, poor feeding, respiratory distress) or if the mother has a history of tuberculosis. Early evaluation is critical to initiate treatment and prevent complications.

Tips for Medical Coders

• Code P37.0 is used for congenital tuberculosis, confirmed by clinical or laboratory evidence of Mycobacterium tuberculosis infection in a newborn.
• Documentation should specify the source of infection (e.g., maternal transmission) and any associated complications (e.g., meningitis, disseminated disease) to support coding accuracy.
• Ensure differentiation from postnatal tuberculosis acquired after birth, which is coded separately.